Table 3.
Name | Keywords | Eigen Value | FREQ | % Cases |
---|---|---|---|---|
Mental health summary | Medical Outcomes Study (MOS); summary; mental; survey; physical; scores; medical; score; health related quality of life (HRQOL); outcomes; short form (SF) | 26.1 | 4123 | 62.60% |
Criteria; controlled trials | Criteria; trials; objectives; controlled; main; evidence; performed; review; evaluate | 1.9 | 2357 | 48.90% |
The World Health Organization Quality of Life brief (WHOQOL-BREF); Domain |
WHOQOL; BREF; Domain; domains; world; version; QOL; psychological; social | 3.3 | 2335 | 44.20% |
Randomized; Controlled trial | Randomized; trial; placebo; controlled; weeks; week; groups; primary; intervention | 7.2 | 2312 | 39.30% |
Cost-effectiveness; costs | Cost; costs; effectiveness; effective; economic; model; year | 1.9 | 1643 | 37.50% |
Coping strategies; social support | Coping; strategies; support; social | 1.3 | 1522 | 37.10% |
Depressive; anxiety and depression | Depressive; depression; symptoms; anxiety; psychiatric; psychological | 2.7 | 1722 | 36.10% |
Reliability and validity; item scale | Validity; reliability; item; items; instrument; factor; scales; measure; good; scale | 2.2 | 1923 | 36.10% |
Care access | Access; services; care | 1.3 | 1220 | 33.40% |
Role functioning | Role; function; cognitive; functioning | 1.5 | 1025 | 27.30% |
Viral load; count | Load; viral; count; counts; cells | 1.8 | 1384 | 27.00% |
Literature; review | Literature; review; evidence | 5 | 919 | 24.10% |
Sex; men and women | Sexual; men; sex; women | 1.8 | 1002 | 23.90% |
Chronic conditions | Conditions; chronic; diseases | 1.6 | 840 | 23.40% |
Stigma; disclosure | Stigma; disclosure; perceived; negative | 3.7 | 837 | 23.20% |
Cross-sectional | Sectional; cross; prevalence | 2.5 | 1128 | 23.00% |
Side effects | Side; effects | 1.5 | 815 | 22.80% |
Follow-up period | Period; follow; month; year | 2.3 | 852 | 22.50% |
Body mass; fat loss | Mass; body; fat; weight; kg; loss; nutritional; exercise; testosterone; index | 3.3 | 1169 | 21.40% |
Drug users | Users; methadone; drug; substance | 2.3 | 766 | 21.00% |
Outcome measures | Outcome; measures | 1.3 | 718 | 20.60% |
Control | Controls; control; intervention | 1.7 | 712 | 20.10% |
Anti; development | Anti; development; resistance; therapeutic | 1.2 | 712 | 19.70% |
Palliative; cancer pain | Palliative; cancer; advanced; pain | 1.9 | 620 | 18.20% |
Adherence to medication | Medication; adherence | 1.6 | 639 | 18.10% |
Developed countries | Countries; developed; settings | 1.2 | 600 | 18.00% |
Screening; early | Screening; early; settings | 1.2 | 500 | 15.50% |
Combination | Combination; response | 1.3 | 416 | 13.50% |
Demographic | Demographic; characteristics | 1.5 | 456 | 13.40% |
Children | Children; adoslescents; caregivers; family | 1.7 | 499 | 13.30% |
EuroQOL (EQ); HRQOL demension | EQ; HRQOL; Dimensions | 1.6 | 445 | 13.30% |
Reduction | Reduction; improvement | 1.4 | 407 | 13.10% |
Morbidity and mortality | Mortality; morbidity | 1.7 | 497 | 12.60% |
Inhibitor; protease inhibitor (PI) regimens | Inhibitor; PI; regimen; regimens | 3.1 | 498 | 12.20% |
Death | Death; hospital | 1.3 | 357 | 12.00% |
Emotional | Emotional; functional | 1.3 | 358 | 11.80% |
Exercise | Exercise; activity; week | 1.3 | 374 | 11.70% |
Moderate to severe | Severe; moderate; haemophilia | 1.5 | 390 | 11.70% |
Long-term | Term; long | 2.1 | 522 | 11.20% |
Adverse effect | Events; adverse | 1.4 | 426 | 11.20% |
Cytomegalovirus (CMV); Prophylaxis | CMV; prophylaxis; infections | 1.4 | 348 | 10.80% |
South Africa | South; Africa | 2 | 344 | 8.60% |
Food | Food; people living with HIV (PLHIV); nutritional | 1.3 | 225 | 6.90% |
Facial | Facial; satisfaction | 1.3 | 177 | 5.90% |
Hepatitis | Hepatitis; hepatitis C virus (HCV) | 1.9 | 215 | 5.60% |
Sleep | Sleep; fatigue | 1.4 | 155 | 4.80% |
Failure | Failure | 1.4 | 120 | 4.30% |
Anemia | Anemia | 1.4 | 49 | 1.70% |
Diarrhea | Diarrhea | 1.5 | 44 | 1.60% |
Tuberculosis (TB) | TB | 1.4 | 38 | 1.40% |